Tohgo A, Tanaka N, Ashida S, Ogawa H
Invasion Metastasis. 1984;4(3):134-45.
The mechanisms by which B16, 3LL and MH134 tumor cells induce platelet aggregation were studied. The B16 and 3LL tumors, which have high or moderate procoagulant activities, aggregated platelets only in the presence of Ca2+ and plasma factors. MH134, which had much lower procoagulant activity, aggregated platelets even in the absence of these factors. The induction of aggregation by B16 and 3LL could be prevented by thrombin inhibitors but not by the ADP scavenger, suggesting that thrombin, generated by procoagulant activities of tumor cells themselves, might play a major role in initiating aggregation. MH134-induced aggregation was not affected by any of the inhibitors, indicating that the mechanisms by which MH134 initiate platelet aggregation are independent of both thrombin and ADP.
研究了B16、3LL和MH134肿瘤细胞诱导血小板聚集的机制。具有高或中度促凝活性的B16和3LL肿瘤,仅在存在Ca2+和血浆因子的情况下使血小板聚集。促凝活性低得多的MH134,即使在没有这些因子的情况下也能使血小板聚集。B16和3LL诱导的聚集可被凝血酶抑制剂阻止,但不能被ADP清除剂阻止,这表明肿瘤细胞自身的促凝活性产生的凝血酶可能在启动聚集中起主要作用。MH134诱导的聚集不受任何一种抑制剂的影响,表明MH134启动血小板聚集的机制独立于凝血酶和ADP。